State of New Jersey Common Pension Fund D Buys 25,337 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

State of New Jersey Common Pension Fund D increased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 32.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 103,456 shares of the biopharmaceutical company’s stock after acquiring an additional 25,337 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Catalyst Pharmaceuticals were worth $2,038,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Federated Hermes Inc. increased its stake in Catalyst Pharmaceuticals by 52.8% in the 3rd quarter. Federated Hermes Inc. now owns 389,289 shares of the biopharmaceutical company’s stock valued at $7,669,000 after buying an additional 134,509 shares during the last quarter. Y Intercept Hong Kong Ltd grew its holdings in shares of Catalyst Pharmaceuticals by 1,216.5% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 165,496 shares of the biopharmaceutical company’s stock valued at $3,260,000 after acquiring an additional 152,925 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in shares of Catalyst Pharmaceuticals by 3,559.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 62,971 shares of the biopharmaceutical company’s stock valued at $1,241,000 after acquiring an additional 61,250 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Catalyst Pharmaceuticals by 957.5% in the third quarter. SG Americas Securities LLC now owns 83,690 shares of the biopharmaceutical company’s stock valued at $1,649,000 after acquiring an additional 75,776 shares during the last quarter. Finally, Cresset Asset Management LLC raised its holdings in Catalyst Pharmaceuticals by 588.1% during the second quarter. Cresset Asset Management LLC now owns 87,418 shares of the biopharmaceutical company’s stock worth $1,897,000 after acquiring an additional 74,713 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on CPRX. Citigroup raised their price target on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Oppenheimer reissued an “outperform” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 7th. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $33.20.

Catalyst Pharmaceuticals Trading Up 2.8%

Shares of NASDAQ CPRX opened at $24.86 on Thursday. The company has a market capitalization of $3.06 billion, a P/E ratio of 14.45, a P/E/G ratio of 0.81 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $26.58. The stock has a 50 day moving average of $23.85 and a 200-day moving average of $22.16.

Insider Activity at Catalyst Pharmaceuticals

In other news, Director Molly Harper sold 26,746 shares of the stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total value of $621,844.50. Following the transaction, the director directly owned 2,360 shares of the company’s stock, valued at $54,870. This represents a 91.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.40% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).